Early benefit assessment: Detailed analysis of all G-BA resolutions

The AMNOG monitor provides current, well-founded analyses of all early benefit assessments and an overview of the negotiated reimbursement prices in Germany. It is an indispensable tool for HTA, market access and pricing managers.
 

List of all G-BA Resolutions

The AMNOG monitor includes detailed analyses of every sinlge benefit assessment since 2011. more >>

Interactive Analysis

Our comprehensive online analysis tool helps answer your individual questions. more >>

Intelligent search

Search for answers in all G-BA resolutions, justifications, IQWiG assessments and much more >>

Reimbursement Price Trends

See the development of manufacturer's prices and yearly therapy costs of all products with negotiated reimbursement prices. more >>

Unrivalled AMNOG Process Knowledge

Gain relevant insights from our summary analysis and our evaluation of all AMNOG resolutions. more >>

 

 

Gain a better insight

Identify decision-paths and trends in early benefit assessment. The AMNOG monitor is indispensable for managers and decision-makers in market access, pricing and reimbursement.

Artificial intelligence (AI) prediction of additional benefits in the German AMNOG-procedure, based on millions of data points of all G-BA resolutions. Competitive intelligence for strategic planning.

Contact us for more information! >>

 

Resolutions December 2022

Dear AMNOG Monitor readers,

The Bundesrat (upper house of the German parliament) approved the GKV-Finanzstabilisierungsgesetz (GKV-FinStG) on October 28, 2022. This means that significant changes in the pricing of new active ingredients that must undergo early benefit assessment have come into force (cf. Bundesregierung). An overview of the most important changes affecting early benefit assessment & pricing can be found here in the AMNOG Monitor.

The new regulations and restrictions will lead to considerable changes for all parties involved.

We wish you a "lucky hand" in this process and hope that you can still enjoy the Advent season.

In November 2022, the G-BA passed 6 new resolutions on early benefit assessments (see table) and started 8 new procedures.

Recent changes in reimbursement prices of AMNOG products can be seen here.
A list of current EMA Positive Opinions for new drugs is available here.

Kind regards,
Dr Johannes Hankowitz and Christian Rieke